0:00
/
Generate transcript
A transcript unlocks clips, previews, and editing.

OCBC and SGX Beat the STI by Double This Year. Here's Where That Return Actually Came From

A breakdown of the earnings growth, price re-rating, and dividend math behind Singapore's two best-performing blue chips this year.

OCBC and SGX have doubled the STI this year, but the math behind their returns tells a different story for income investors. I walk through OCBC’s 13% profit jump to 4.2 billion and 47-cent interim dividend, then show why the trailing yield now sits at 2.79%, missing my 3.2% floor. SGX posted record revenue of 1.5 billion and lifted its dividend to 57 cents, yet its yield also falls short as the share price runs into record territory. We also touch on Yangzijiang’s 28% profit surge and why its dividend question sits outside this year’s rally.
Key takeaways:

  • OCBC H1 net profit up 13% to 4.2 billion, interim dividend raised to 47 cents

  • OCBC’s trailing yield now 2.79%, 41 basis points below the 3.2% income hurdle

  • SGX FY2026 revenue up 13.9% to 1.5 billion, dividend up to 57 cents including a one-off

  • SGX’s record share price compresses its yield despite strong dividend growth

  • Yangzijiang H1 profit up 28% to 5.4 billion yuan, no interim dividend declared

This Substack is reader-supported. To receive new posts and support my work, consider becoming a free or paid subscriber.


Iggy’s Forensic Disclaimer

This content is produced for educational and informational purposes only. I am not a financial advisor — I am a retail investor who applies forensic analysis to my own portfolio and shares that process publicly. Nothing here constitutes a recommendation to buy, sell, or hold any security, and no specific target prices or personalised financial advice are offered. Stocks assessed under Iggy’s Forensic Yield Standard are benchmarked against a 4.7% minimum yield hurdle; stocks flagged as Growth Watch fall below this threshold but demonstrate clean balance sheet metrics and an identifiable growth catalyst — these carry a materially different risk profile and are not suitable as yield replacements for income-dependent investors. All data is sourced from public filings and verified sources; where data is unverified it is explicitly flagged. All investments carry risk, including the potential loss of principal, and past performance is not indicative of future results. If you are making investment decisions involving CPF, SRS, or personal capital, please conduct your own due diligence or consult a MAS-licensed financial adviser before committing funds.

Discussion about this video

User's avatar

Ready for more?